Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis-a serological evaluation

被引:44
作者
Leeming, Diana J. [1 ]
Byrjalsen, Inger [1 ]
Jimenez, Wladimiro [2 ,3 ]
Christiansen, Claus [1 ]
Karsdal, Morten A. [1 ]
机构
[1] Nord Biosci, Fibrosis Biol & Biomarkers, Herlev, Denmark
[2] Univ Barcelona, Serv Biochem & Mol Genet, Dept Physiol Sci 1, Inst Invest Biomed August Pi i Sunyer IDIBAPS,Hos, Barcelona, Spain
[3] Univ Barcelona, Dept Physiol Sci 1, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
关键词
biochemical markers; CCl4; model; Collagens; connective tissue; Protoglycans; LINKED-IMMUNOSORBENT-ASSAY; NONINVASIVE ASSESSMENT; BIOCHEMICAL MARKERS; CCL4-TREATED RATS; HEPATIC-FIBROSIS; UP-REGULATION; IV COLLAGEN; 7S DOMAIN; PROCOLLAGEN; PROGRESSION;
D O I
10.1111/liv.12044
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aim We investigated nine novel biomarkers of extracellular matrix (ECM) remodelling in a rat model of liver fibrosis. Methods Liver fibrosis was induced in 52 male Wistar rats by inhalation of carbon tetrachloride and the level of hepatic fibrosis was assessed by Sirius red staining compared with controls. The novel serum biochemical markers assessed in the model were type I-(C1M), type III-(C3M), type IV-(C4M) and type VI-(C6M) collagen, citrullinated vimentin (VICM) and biglycan (BGM) all protein fragments generated by matrix metalloproteinases; and formation markers of type III-(P3NP), type VI (P4NP 7S) and type V (P5CP) collagen; hepatic mRNA type I collagen alpha-1 chain levels, serum potassium, sodium, osmolarity, alanine aminotransferase, lactate dehydrogenase, albumin and creatinine. Results Stratification of the CCl4-treated rats according to total hepatic collagen showed that the degradation markers were significantly elevated in mild to severe fibrosis except for C6M which was also elevated in early fibrosis (P<0.05). The highest Z-scores in early and moderate fibrosis were provided by P4NP 7S and alanine aminotransferase. All nine markers of ECM remodelling were highly related to the extent of liver fibrosis induced by CCl4. The novel collagen formation marker, P4NP 7S, was reliable for the detection of early fibrosis, while the combination of the two markers, C6M and P5CP provided the best correlation with hepatic fibrosis in all fibrosis levels. Conclusion As the markers can be used for translational science, these markers may provide valuable information for the evaluation of liver fibrosis in clinical settings.
引用
收藏
页码:439 / 447
页数:9
相关论文
共 38 条
[11]   Liver fibrosis - from bench to bedside [J].
Friedman, SL .
JOURNAL OF HEPATOLOGY, 2003, 38 :S38-S53
[12]   Interleukin-1 participates in the progression from liver injury to fibrosis [J].
Gieling, Roben G. ;
Wallace, Karen ;
Han, Yuan-Ping .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2009, 296 (06) :G1324-G1331
[13]   Accelerated development of liver fibrosis in CCl4-treated rats by the weekly induction of acute phase response episodes: Upregulation of alpha 1(I) procollagen and tissue inhibitor of metalloproteinase-1 mRNAs [J].
Greenwel, P ;
Rojkind, M .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1997, 1361 (02) :177-184
[14]   Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets [J].
Gressner, A. M. ;
Weiskirchen, R. .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2006, 10 (01) :76-99
[15]   Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality [J].
Gressner, O. A. ;
Weiskirchen, R. ;
Gressner, A. M. .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2007, 11 (05) :1031-1051
[16]   Biomarkers of liver fibrosis: Clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests [J].
Gressner, Olav A. ;
Weiskirchen, Ralf ;
Gressner, Axel M. .
CLINICA CHIMICA ACTA, 2007, 381 (02) :107-113
[17]   Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and Other Modalities [J].
Guha, In ;
Rosenberg, W. M. .
CLINICS IN LIVER DISEASE, 2008, 12 (04) :883-+
[18]   Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development [J].
Karsdal, M. A. ;
Henriksen, K. ;
Leeming, D. J. ;
Mitchell, P. ;
Duffin, K. ;
Barascuk, N. ;
Klickstein, L. ;
Aggarwal, P. ;
Nemirovskiy, O. ;
Byrjalsen, I. ;
Qvist, P. ;
Bay-Jensen, A. C. ;
Dam, E. B. ;
Madsen, S. H. ;
Christiansen, C. .
BIOMARKERS, 2009, 14 (03) :181-202
[19]   Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? [J].
Karsdal, Morten Asser ;
Henriksen, Kim ;
Leeming, Diana Julie ;
Woodworth, Thasia ;
Vassiliadis, Efstathios ;
Bay-Jensen, Anne-Christine .
CLINICAL BIOCHEMISTRY, 2010, 43 (10-11) :793-804
[20]   Expression of Matrix Metalloproteinases 2 and 9 in Donor Liver, Cirrhotic Liver, and Acute Rejection After Human Liver Transplantation [J].
Kirimlioglu, H. ;
Kirimlioglu, V. ;
Yilmaz, S. .
TRANSPLANTATION PROCEEDINGS, 2008, 40 (10) :3574-3577